Interferon-driven gene signature identifies two distinct subgroups in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis
- 8 September 2026
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (10)
Abstract
Objective: To characterize the demographic, clinical, serological, genetic background, course and value of the interferon (IFN) score in a cohort of patients with rheumatoid factor (RF)-positive polyarticular juvenile idiopathic arthritis (pJIA). Methods: Monocentric retrospective study of patients with RF-positive pJIA. Demographic, clinical and laboratory data were collected. The IFN score was calculated based on the expression levels of 24 IFN stimulated genes. Whole exome sequencing was performed in 22 patients. Results: Thirty-two patients were included. The IFN score was positive in 18 patients (56.2%) and negative in 14 patients (43.7%). An increased IFN score was associated with a significantly higher family history of autoimmunity (P = 0.0004), parental first-degree consanguinity (P = 0.05) and prevalence of antibodies to anti-cyclic citrullinated peptide (ACPA) (P = 0.01). Three patients with interstitial lung disease exhibited a positive IFN score. Conversely, demographic features and characteristics of polyarthritis did not differ between the two groups. Clinically inactive disease was achieved in 21/32 (66%) patients, with no significant difference according to the IFN score. Remission was never achieved with methotrexate alone. We identified one patient with a pathogenic de novo mutation in COPA. Additionally, ultra-rare variants in genes related to IFN and/or innate immunity were found in 21/22 (95.5%) patients. Conclusion: The IFN signature identified two distinct subgroups in RF-positive pJIA according to family history and immunological features. Our study suggests that patients with an elevated IFN score should be screened for pulmonary involvement. Future prospective studies are required to validate the use of the IFN score as a biomarker in RF-positive pJIA.Keywords
Funding Information
- Fondation Maladies Rares
- Fondation Bettencourt-Schueller ‘Poste CCA-Bettencourt’
This publication has 25 references indexed in Scilit:
- Rheumatoid Arthritis‐Associated Interstitial Pneumonia Refractory to Initial Therapy: Successful Control Through Combined Anti‐Inflammatory, Antifibrotic and JAK ‐ STAT ‐Targeted TreatmentRespirology Case Reports, 2025
- Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2025
- Genetic Association of Juvenile Idiopathic Arthritis With Adult Rheumatic DiseaseJAMA Network Open, 2024
- Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltrationCell Reports, 2024
- Role of IFN-α in Rheumatoid ArthritisCurrent Rheumatology Reports, 2023
- Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trialThe Lancet, 2023
- Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 PatientsThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapyJournal of Allergy and Clinical Immunology, 2018
- American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritisArthritis Care & Research, 2011
- Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: Ethnicity as a risk factorArthritis & Rheumatism, 2007